Borisow, Nadja
Hellwig, Kerstin
Paul, Friedemann
Article History
Received: 24 May 2018
Accepted: 11 July 2018
First Online: 10 August 2018
Compliance with ethical standards
:
: For this type of study, formal consent is not required.
: N. Borisow declares no conflict of interest.F. Paul is a member of the scientific advisory board of Novartis; has received lecture fees and travel reimbursement from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is academic editor of PLoS One, Associate Editor of Neurology® Neuroimmunology & Neuroinflammation; consulted for Sanofi-Genzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, the German Research Foundation, the Werth Foundation of the city of Cologne, the German Federal Ministry of Research and Education, the Arthur Arnstein Stiftung Berlin, the EU FP7 Framework Program, Jackson Charitable Foundation, and the National Multiple Sclerosis of the USA.K. Hellwig received consultant and lecture fees and research support from Bayer Healthcare, Biogen, Novartis Pharma, Teva Pharma, Roche, and Sanofi-Genzyme und Merck.The NEMOS cohort/NationNMO is supported by the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (KKNMS; for NEMOS NationNMO-LAB FKZ 01GI1602A to B.W., NationNMO-PAT FKZ 01GI1602B to O.A., and NationNMO-DAB FKZ 01GI1602C to J.S.).
: This paper included no studies of humans or animals.